PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS

PB2019: PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS

Bibliographic Details
Main Authors:	Guillermo Garcia-Manero, Lewis Silverman, Lucy Yan, Wolfgang Dummer
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000974884.91552.90

Similar Items

Research and clinical updates on IRAK4 and its roles in inflammation and malignancy: themes and highlights from the 1st symposium on IRAK4 in cancer
by: Guillermo Garcia-Manero, et al.
Published: (2024-02-01)

Inhibition of IRAK1 Is an Effective Therapy for Autoimmune Hypophysitis in Mice
by: Hsiao-Chen Huang, et al.
Published: (2022-11-01)

P763: VENETOCLAX WITH AZACITIDINE IN RELAPSE/REFRACTORY HIGHER RISK MYELODYSPLASTIC SYNDROME: UPDATED PHASE 1 RESULTS
by: S. P. Desikan, et al.
Published: (2022-06-01)

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME
by: Courtney Dinardo, et al.
Published: (2023-08-01)

The Alphaviral Capsid Protein Inhibits IRAK1-Dependent TLR Signaling
by: V. Douglas Landers, et al.
Published: (2021-02-01)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
by: Georgia Tsekoura, et al.
Published: (2023-08-01)

Quercetin Alleviates Osteoarthritis Progression in Rats by Suppressing Inflammation and Apoptosis via Inhibition of IRAK1/NLRP3 Signaling
by: Li W, et al.
Published: (2021-07-01)

Safety and efficacy of azacitidine in myelodysplastic syndromes
by: Carlos E Vigil, et al.
Published: (2010-09-01)

Diversity of the bovine genes IRAK1 and IRAK4 in the Toll-like receptor signaling pathway
by: Ladislav Tichý, et al.
Published: (2023-08-01)

IRAK-M suppresses the activation of microglial NLRP3 inflammasome and GSDMD-mediated pyroptosis through inhibiting IRAK1 phosphorylation during experimental autoimmune encephalomyelitis
by: Yuanyuan Wang, et al.
Published: (2023-02-01)

B cell antigen receptor-induced activation of an IRAK4-dependent signaling pathway revealed by a MALT1-IRAK4 double knockout mouse model
by: Dufner Almut, et al.
Published: (2011-03-01)

Autoimmune pulmonary alveolar proteinosis prior to myelodysplastic syndrome
by: Chuan Tai Foo, et al.
Published: (2020-07-01)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
by: Nouha Bouayed Abdelmoula, et al.
Published: (2023-08-01)

Plasma protein alterations in the refractory anemia with excess blasts subtype 1 subgroup of myelodysplastic syndrome
by: Májek Pavel, et al.
Published: (2012-05-01)

PB2017: CLINICAL OUTCOMES BY SF3B1 MUTATION STATUS IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES RETREATED WITH ERYTHROPOIESIS-STIMULATING AGENTS
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

A rare case of myelodysplastic syndrome with refractory thrombocytopenia
by: Waqas Jehangir, et al.
Published: (2015-09-01)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
by: Guillermo Garcia-Manero, et al.
Published: (2023-08-01)

Dossier Irak
by: Diego Cardona, et al.
Published: (2017-09-01)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME: A FIRST-IN-CLINIC PHASE 1 STUDY OF GSK3745417
by: Pau Montesinos, et al.
Published: (2023-08-01)

IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
by: Ricardo D. Parrondo, et al.
Published: (2023-10-01)

Inhibition of IRAK 1/4 alleviates colitis by inhibiting TLR4/ NF-κB pathway and protecting the intestinal barrier
by: Bo Yan, et al.
Published: (2022-10-01)

S129: TAKEAIM LEUKEMIA- A PHASE 1/2A STUDY OF THE IRAK4 INHIBITOR EMAVUSERTIB (CA-4948) AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN RELAPSED/REFRACTORY AML OR MDS
by: G. Garcia-Manero, et al.
Published: (2022-06-01)

Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants
by: Thomas Hoyler, et al.
Published: (2022-07-01)

BAP31 regulates IRAK1-dependent neuroinflammation in microglia
by: Xia Liu, et al.
Published: (2019-12-01)

Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
by: Panpan Wang, et al.
Published: (2020-06-01)

Dingchuan tang essential oil inhibits the production of inflammatory mediators via suppressing the IRAK/NF-κB, IRAK/AP-1, and TBK1/IRF3 pathways in lipopolysaccharide-stimulated RAW264.7 cells
by: Zhang Y, et al.
Published: (2018-09-01)

P765: UPDATED ENROLLMENT AND RESULTS FROM THE PHASE 1 SUBSTUDY OF IVOSIDENIB IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME (R/R MDS)
by: C. D. DiNardo, et al.
Published: (2022-06-01)

Internflyktningskap i Irak
by: Mariette Hägglund
Published: (2023-11-01)

¿Irak en transición?
by: Diego Fernández Gabaldón
Published: (2005-01-01)

¿Irak en transición?
by: Diego Fernández Gabaldón
Published: (2006-01-01)

Pacritinib Inhibition of IRAK1 Blocks Aberrant TLR8 Signalling by SARS-CoV-2 and HIV-1-Derived RNA
by: Grant R. Campbell, et al.
Published: (2022-07-01)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
by: Imen Ben Amor, et al.
Published: (2023-08-01)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
by: Yamina Bouchakour Moussa, et al.
Published: (2023-08-01)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
by: Tamar Saralidze, et al.
Published: (2023-08-01)

Identification of IRAK1BP1 as a candidate prognostic factor in lung adenocarcinoma
by: Lei Guo, et al.
Published: (2023-03-01)

Genetics of Myelodysplastic Syndromes
by: Caner Saygin, et al.
Published: (2021-07-01)

De Irak (1991) a Irak (2016): Evolución del pensamiento militar contemporáneo
by: Ángel Gómez de Ágreda
Published: (2016-12-01)

The IRAK1/IRF5 axis initiates IL-12 response by dendritic cells and control of Toxoplasma gondii infection
by: Milton Pereira, et al.
Published: (2024-02-01)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
by: Pellagatti, A, et al.
Published: (2009)

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
by: Yossra Aghoutane, et al.
Published: (2023-08-01)